gastrocon 2016 - drug induced liver disease
TRANSCRIPT
![Page 1: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/1.jpg)
DRUG INDUCED LIVER DRUG INDUCED LIVER DISEASE DISEASE
S. P. SINGHS. P. SINGH
![Page 2: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/2.jpg)
DEFINITIONDEFINITIONThe liver disease The liver disease resulting from the resulting from the inhalation, ingestion or parenteral inhalation, ingestion or parenteral administration administration of any pharmacological or of any pharmacological or chemical agent is called drug induced liver chemical agent is called drug induced liver disease disease (DILD)(DILD)
![Page 3: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/3.jpg)
DRUG HEPATITIS !DRUG HEPATITIS !
DILIDILI [Drug Induced Liver [Drug Induced Liver Injury]?Injury]?
![Page 4: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/4.jpg)
Drug Induced Liver Drug Induced Liver DisordersDisorders
• When Liver Biopsy has been performed: lesion should be named according to histological findings, e.g. ‘cirrhosis’, ‘CLD’,’hepatic necrosis’ or ‘hepatitis’.
• In the absence of histological data: such terms should not be used. The preferred term is “liver injury”.
CIOMS
![Page 5: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/5.jpg)
LIVER INJURY• This term should be used if there is an
increase in over 2 N in ALT [alanine aminotransferase] or CB [Conjugated Bilirubin]
OR• Combined increase in AST [aspartate
aminotransferase], AP [Alk Phos] & TB [Total Bil] provided one of them is above 2N.
CIOMS
![Page 6: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/6.jpg)
LIVER INJURY• Hepatocellular: Increase of over 2N in
ALT alone or R ≥ 5 [R = serum activity of ALT/serum activity of AP – each expressed as multiple of N]
• Cholestatic: Increase in over 2N in AP alone or R ≤ 2.
• Mixed: Both ALT above 2N & AP are increased, & 2 < R < 5
CIOMS
![Page 7: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/7.jpg)
ABNORMALITIES OF LIVER TESTS
• Isolated increase even over 2N in AST, AP or TB should be considered only a biochemical abnormality and not necessarily a sign of liver injury
• When the increase in ALT, AST, AP or TB is between N & 2N, the term – ‘abnormality of liver tests’ should be used & not ‘liver injury’.
CIOMS
![Page 8: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/8.jpg)
CLINICAL CLINICAL FEATURESFEATURES
Drugs can cause nearly anytype of liver disorder and can mimic many well-recognized clinical syndromes
![Page 9: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/9.jpg)
CLINICAL FEATURES• Abnormal liver tests• Acute viral hepatitis-like injury• Acute [fulminant] liver failure• Cholestatic hepatitis• Liver disease with signs of
hypersensitivity• Autoimmune hepatitis-like injury• Acute venous outflow
obstruction• Obstructive jaundice-like• Chronic cholestasis• Cirrhosis• Primary hepatic neoplasms
![Page 10: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/10.jpg)
DRUG INDUCED LIVER DISEASE[CLINICO-PATHOLOGICAL TYPES]
HEPATOCELLULAR CHOLESTATIC
VASCULAR
MIXED
STEATOSIS
TUMOR
GRANULOMATOUS
![Page 11: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/11.jpg)
MECHANISMS OF HEPATOTOXICITY
• Intrinsic hepatotoxins• Idiosyncratic hepatotoxins Hypersensitivity Metabolic Idiosyncrasy• Damage to the genome?
![Page 12: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/12.jpg)
![Page 13: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/13.jpg)
The hepatocyte in the center of the field is under-going apoptosis, while the other liver cells are swollen or ballooned. The inflammatory response is predomi-nantly lymphocytic.
Acute hepatitis-like injury in a patient taking INH
![Page 14: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/14.jpg)
Submassive (zone 3) hepatic necrosis, Lytic type, following halothane anesthesia
![Page 15: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/15.jpg)
Submassive (zone 3) coagulative necrosis caused by an overdose of acetaminophen
![Page 16: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/16.jpg)
The biopsy on the left has relatively ‘bland”Cholestasis. Biopsy on the right shows a com-bined hepatocellular and cholestatic injury
![Page 17: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/17.jpg)
HEPATOCELLULAR & CANALICULAR CHOLESTASISBile is present within transversely (open arrow) or long-itudinally sectioned bile canaliculi (long arrows). Several hepatocytes at upper right (curved arrows) contain bile
![Page 18: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/18.jpg)
Granulomatous hepatitis in a patient taking phenylbutazone
![Page 19: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/19.jpg)
Severe chronic hepatitis in a patient who had taken α-methyldopa for 3 months
![Page 20: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/20.jpg)
Severe liver injury in an atypical pattern, suggesting a drug-induced cause
![Page 21: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/21.jpg)
Amiodarone phospholipidosis: foam cells and Mallory bodies
![Page 22: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/22.jpg)
LIVER BIOPSY FINDINGS THAT SUGGEST DRUG HEPATOTOXICITY
• Prominent Eosinophils in inflammatory infiltrate
• Granulomatous Hepatitis with granulomas + hepatitis-like hepatocellular injury
• Cholestatic Hepatitis: combined hepatocellular & cholestatic injury
• Severe acute injury• Any unusual combination of
histologic findings, atypical for any of the common primary liver diseases.
![Page 23: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/23.jpg)
NAILING THE CULPRIT
![Page 24: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/24.jpg)
NAILING THE CULPRIT • Drug induced Liver disease can
simulate nearly any clinical syndrome or pathologic lesion.
• Diagnosis can not be made on morphologic grounds alone or on the basis of specific laboratory test !
• Careful correlation of history with clinical, laboratory & histologic data.
![Page 25: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/25.jpg)
In every instance, the morphologic findings must be correlated with the following
• A complete drug or chemical history: All exposures must be considered.
• Specific and detailed time-related drug information: It is essential to know exactly when the drug was taken in relation to the signs, symptoms, and laboratory evidence of liver disease.
• The results of the laboratory tests: These are essential in determining the onset, duration, and degree of injury.
![Page 26: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/26.jpg)
The following should be determined from the history and lab studies:
• Temporal eligibility • Exclusion of other causes • Precedent • Pattern of injury • Dechallenge and rechallenge • Toxicologic analysis
![Page 27: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/27.jpg)
TEMPORAL ELIGIBILITY
• Did the administration of the drug precede the onset of the liver disease by a reasonable time interval (latent period) for that drug?
• An obvious but often overlooked point is that if the patient was already ill when he or she began taking the suspected drug, then the drug could not have caused the illness
• It is also important to recognize that each drug that can cause liver injury does so after a latent period that is characteristic for that drug. In most cases, this is approximately 3 weeks to 3 months
• If a drug has been taken regularly with no problems for years, it is extremely unlikely that it is responsible for a newly recognized injury
![Page 28: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/28.jpg)
“Other causes besides the suspected drug need to be carefully considered and
excluded if possible”
EXCLUSION
![Page 29: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/29.jpg)
PRECEDENT • Any drug that has been in use for some
time will have a record that can be used to assess the likelihood of its having caused the suspected injury
• However, any newly marketed drugs that the patient has taken should be considered too although they will not have a track record
• When a list of drugs and dates has been assembled, each drug should be checked for potential hepatotoxicity
• Resources: Physicians' Desk Reference & Medline-PubMed database [http://www.nchi.nlm.nih.gov/entre2/query.fcgi]
![Page 30: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/30.jpg)
PATTERN OF INJURY• Pattern of injury produced by each
drug tends to be consistent, or at least falls within a defined range.
• For example, some drugs, such as erythromycin, typically produce cholestatic injury, wherease others, such as isoniazid, are nearly always hepatocellular.
• The literature search is often helpful in establishing whether the type of injury seen in an individual case is typical or unusual for the suspected drug and will contribute to the assessment of the likelihood of a drug-induced cause
![Page 31: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/31.jpg)
DECHALLENGE & RECHALLENGE
• Dechallenge and rechallenge are very helpful in the final analysis
• If the patient recovers after the drug is stopped, the likelihood that the drug was the cause is increased
• However, lack of recovery does not always exclude the drug. In particular, recovery from a cholestatic injury can be very prolonged
![Page 32: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/32.jpg)
RECHALLENGE• Deliberate rechallenge is never
recommended, because it puts the patient at risk for a more serious injury
• However if a drug is inadvertently readministered (eg, before it was suspected), the prompt return of the injury is extremely strong evidence that the drug is the causative agent
![Page 33: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/33.jpg)
TOXICOLOGY• Toxicologic analysis of blood, tissue,
or other body fluids can establish direct toxicity (overdose or poisoning) in selected cases only.
• In most cases, however, drug hepatotoxicity is caused by idiosyncratic reactions, and so toxicology is of no use.
![Page 34: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/34.jpg)
INTERNATIONAL CONSENSUS CRITERIAfor Diagnosis of drug induced
hepatotoxicity• The time from drug intake and withdrawal to the
apparent onset of the reaction was "suggestive" (5-90 days from initial drug intake) or "compatible" (less than five or more than 90 days from initial drug intake and not more than 15 days of drug withdrawal for "hepatocellular" reaction and not more than 30 days of drug withdrawal for cholestatic reaction) with drug hepatotoxicity.
• Course of the reaction after cessation of the drug was "very suggestive" (decrease in the liver enzymes by at least 50% of the excess over the upper limit of normal within eight days) or "suggestive" (decrease in the liver enzymes by at least 50% within 30 days for "hepatocellular" reaction and 180 days for "cholestatic" reaction) of drug reaction.
• Alternative cause of the reaction had been excluded by detailed investigations, including a liver biopsy in each case.
• There was a positive response to rechallenge (at least a doubling of liver enzymes) when such information was available. J Hepatol 1990;11:272-276
![Page 35: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/35.jpg)
FINALLY AFTER A CASE HAS BEEN EVALUATED, IT CAN BE CLASSIFIED ON THE BASIS OF ‘CERTAINTY’
• Causative: Cases in which toxicologic analysis establishes a drug level in the toxic range.
• Probable: Cases in which the drug is temporally eligible and in which the type of tissue injury is the same as that observed in previous experience with the drug.
• Possible: Cases in which the type of injury can be associated with the drug but in which other factors or possible causes cannot be excluded.
• Coincidental: Cases in which drug-induced disease appears to be most unlikely but cannot be absolutely denied.
• Negative: Cases in which the possibility of a drug injury can be clearly eliminated.
![Page 36: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/36.jpg)
HEPATOTOXICITY SCALES• Council for International
Organizations of Medical Sciences (CIOMS) scale
• Maria & Victorino (M&V) Clinical scale or CDS [Clinical Diagnostic Scale]
![Page 37: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/37.jpg)
CLINICAL DIAGNOSTIC SCALECOMPONENT ELEMENTS
I. Temporal relationship between drug intake and the reaction
II. Exclusion of alternative causesIII. Extrahepatic manifestationsIV. Intentional or accidental re-exposure
to the drugV. Previous report in the literature of
cases of hepatotoxicity associated with the drug
Maria & Victorino (M&V)
![Page 38: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/38.jpg)
Scores for Individual Axes of the M&V Diagnostic
Scale
• From drug intake until onset event +1 to+3 • From drug withdrawal until onset event -3 to +3 • Course of the reaction 0 to +3• Exclusion alternative causes -3 to +3• Extrahepatic manifestations 0 to +3• Bibliographic data -3 to +2• Rechallenge 0 to +3
Axis Score
![Page 39: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/39.jpg)
TEMPORAL RELATIONSHIP BETWEEN DRUG INTAKE & REACTION
• Time: Intake – Onset of 1st clinical or Lab manifestation
4 Days – 8 Weeks 3 < 4 Days or > 8 Weeks 1• Time: Drug withdrawal – Onset of
manifestations 0 – 7 Days 3 8 – 15 Days 0 > 15 Days -3• Time: Drug withdrawal – Normalization of
Lab values [Decrease to values 2 x ULN] < 6 mo [Chole/mixed] or 2 mo [Hep] 3 > 6 mo [Chole/mixed] or 2 mo [Hep] 0
Clinical Diagnostic Scale
![Page 40: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/40.jpg)
EXCLUSION OF ALTERNATIVE CAUSES
• Complete Exclusion: 3• Partial Exclusion: 0• Possible alternate cause detected -1• Probable alternative cause detected -1
![Page 41: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/41.jpg)
EXTRAHEPATIC MANIFESTATIONS
[rash, fever, arthralgia, eosinophilia, cytopenia]
• 4 or more 3• 2 or 3 2• 1 1• None 0
![Page 42: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/42.jpg)
CLINICAL DIAGNOSTIC SCALE: CONTINUED
• INCIDENTAL / ACCIDENTAL RE-EXPOSURE Positive re-challenge test 3 Negative or absent re-challenge test 0
• PREVIOUS REPORT IN LITERATURE OF DILI Yes 2 No [drugs marketed for up to 5 years] 0 No [drugs marketed for > 5 years] -3
![Page 43: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/43.jpg)
CDS: VALIDITY• CDS score of > 9 identified the cases
of drug-related hepatotoxicity with 88% sensitivity and 92% specificity.
• Patients with scoring ≤ 9 on CDS scale require further investigation & / or follow-up.
• CDS scoring useful in evaluation of suspected hepatotoxic drug reactions
Aithal et al, J Hepatol 2000
![Page 44: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/44.jpg)
Scores for Individual Axes of the CIOMS Scale
• From drug intake until onset event +2 to+1 • From drug withdrawal until onset event +1 to 0 • Course of the reaction +1 to 0 Risk factors • Age +1 to 0 • Alcohol +1 to 0 • Concomitant therapy -3 to 0• Exclusion non-drug-related causes -3 to +2 • Bibliographic data 0 to +2• Rechallenge -2 to +3
Axis Score
![Page 45: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/45.jpg)
Summary of “Diagnosis”
• Drug-induced liver disease is a relatively common, but often unrecognized, cause of liver injury
• Drugs are great imitators, capable of producing nearly any clinical scenario and histopathologic lesion
• When dealing with a liver biopsy from a patient with an undiagnosed liver disease, the diagnosis of drug hepatotoxicity is made by first having a high index of suspicion, and then by careful correlation
![Page 46: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/46.jpg)
MANAGEMENT ?
![Page 47: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/47.jpg)
PREVENTION OF DILD
• With the exception of acetaminophen hepatotoxicity , there is little effective treatment for drug-induced liver disease.
• All physicians must report suspected adverse effects to monitoring agencies or publish them.
• Minimize DILI through avoidance of overuse of hepatotoxic drugs; avoid polypharmacy.
• For dose-dependent hepatotoxins, prevention depends on adherence to dosage guidelines or use of blood levels.
![Page 48: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/48.jpg)
ACTIVE MANAGEMENT • Active management might include removal
of the drug and the administration of antidotes and anti-inflammatory and cytoprotective agents. In practice, management is usually confined to discontinuation of hepatotoxic drugs.
• For ingested toxins like metals, poisonous mushrooms, and acetaminophen,removal of unabsorbed drug through the aspiration of stomach contents may be appropriate.
• Thiol replacement therapy, usually N-acetylcysteine (NAC), is indicated as an antidote for acetaminophen poisoning .
![Page 49: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/49.jpg)
ACTIVE MANAGEMENT• Beyond discontinuation of the
offending agent, the management of drug hepatitis and cholestasis is symptomatic and supportive.
• In cases of acute liver failure, hepatic transplantation should be considered.
![Page 50: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/50.jpg)
ACTIVE MANAGEMENT• Ursodeoxycholic acid has some promise
for chronic cholestasis and pruritus.• Glucocorticoids have little role in the
management of drug-induced cholestasis or hepatitis and are ineffective in chlorpromazine-, methyldopa-, and isoniazid-induced hepatitis and in drug-induced fulminant hepatic failure.
• Case reports attest to their occasional effectiveness in protracted cases of hepatitis caused by etretinate, allopurinol, diclofenac, or ketoconazole.
• Glucocorticoids should be reserved for atypical and refractory cases, particularly those with vasculitis.
![Page 51: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/51.jpg)
THANK YOU
![Page 53: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/53.jpg)
![Page 54: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/54.jpg)
![Page 55: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/55.jpg)
Measures proposed to reduce risk of severe hepatic adverse effects during ATT • First, patients with underlying liver test
abnormalities should not be given pyrazinamide. • Second, isoniazid & pyrazinamide should be
administered at the lowest dosage within their respective therapeutic ranges.
• Third, Se transaminase levels should be determined twice weekly during first 2 wks of treatment, every 2 wks during the rest of the first 2 mos, and every mo thereafter.
Durand et al, 1996
![Page 56: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/56.jpg)
Measures proposed to reduce risk of severe hepatotoxicity during ATT
• When Se transaminase ↑to > 3 times ULN, therapy with isoniazid, rifampicin and pyrazinamide should be stopped.
• After Se transaminase levels have returned to normal, INH can be re-introduced at a low daily dose, without rifampicin.
• Pyrazinamide may not be re-introduced: risk of recurrence & poor prognosis of pyrazinamide-induced hepatitis.
• Although nephrotoxic, streptomycin is an alternative in patients with LFT abnormalities during ATT.
Durand et al, 1996
![Page 57: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/57.jpg)
![Page 58: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/58.jpg)
Challenge Reintroduction Dosages
• Isoniazid: Introduce at 50 mg/day; increase sequentially
to 300 mg/day after 2–3 days if no reaction occurs, and then continue.
• Rifampicin: Added after a further 2–3 days without
reaction: 75 mg/day increase to 300 mg after 2–3 days, & then to 450 mg (<50 kg) or 600 mg (>50 kg) as appropriate after further 2–3 days without reaction, and then continued.
• Pyrazinamide: Added finally: 250 mg/day, increase to 1.0 g
after 2–3 days; then to 1.5 g (<50 kg) or 2 g (>50 kg).
![Page 59: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/59.jpg)
![Page 60: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/60.jpg)
Clinical Infectious Diseases 2010; 50:833–839.
![Page 61: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/61.jpg)
Three Different Regimens for Reintroduction of Anti-Tuberculosis Drugs
SK Sharma et al. Clinical Infectious Diseases 2010
![Page 62: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/62.jpg)
SK Sharma et al. Clinical Infectious Diseases 2010
Summary of the ATT Re-introduction Study
![Page 63: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/63.jpg)
![Page 64: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/64.jpg)
Acetaminophen induced DILI
N-Acetylcysteine (NAC)
![Page 65: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/65.jpg)
Acetaminophen induced DILI
• N-acetylcysteine reduces mortality even if commenced late
• Reduces Inotrope Requirements• Decreases Cerebral Edema • Increases the rate of survival by
about 30%30%*
* Keays et al. IV NAC in paracetamol induced FHF: A prospective controlled trial. BMJ 1991
![Page 66: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/66.jpg)
Valproate induced DILI
• IV Carnitine*• Overcomes inhibition of β-oxidation of
Fatty Acids caused by Valproate• Also ↑es β-oxidation of Valproate• IV is better than Oral supplementation*• ↑ Survival*
* Bohan et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001
![Page 67: Gastrocon 2016 - Drug Induced Liver Disease](https://reader035.vdocuments.us/reader035/viewer/2022062316/5877100a1a28ab890e8b7047/html5/thumbnails/67.jpg)
• Silymarin alone or combination of Silymarin + Benzylpenicillin for Mushroom (Amanita phalloides) toxaicity1
• Corticosteroids:can be attempted in cholestatic hepatitis with f/o hypersensitivity (rash & fever)2
1. Enjalbert et al. Treatment of amatoxin poisoning: 20-yr retrospective analysis. J Toxicol Clin Toxicol 2002
2. Giannattasio et al. Steroid therapy for a case of severe DILI. Ann Pharmacother. 2006